Nutrition and the Prevention and Treatment of Cancer: Association of Cytochrome P450 CYP1B1 With the Role of Fruit and Fruit Extracts

Abstract

Recommendations for a healthy or prudent diet include a large number of daily servings of fruits and vegetables, and these 2 classes of food are widely believed to assist in cancer prevention. One potential mechanism that is rarely mentioned in nutritional studies involves the cytochrome P450 enzyme CYP1B1, which appears to have the unique properties of being a universal cancer marker overexpressed in cancer cells and having the capability of converting various phytochemicals and synthetic chemicals into substances cytotoxic to these cells. Although these particular features of CYP1B1 have not gone unnoticed, there has been relatively little research aimed at exploiting them. Furthermore, therapeutic and preventive strategies currently being considered based on vaccines against the enzyme or inhibition without the generation of cytotoxins can be questioned because they do not take advantage of the unique properties of this enzyme. In addition, a few relevant case histories have been published that use specially designed fruit extracts containing substrates with demonstrated cytotoxic metabolic products, and these reports provide an initial confirmation of the potential of exploiting the unusual properties of this enzyme for cancer therapy.

Keywords

CYP1B1 fruit extracts cytotoxins phytochemicals natural cancer therapy

References

Murray GI , Melvin WT , Greenlee WF , Burke MD Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1 . Annu Rev Pharmacol Toxicol. 2001;41:297-316.

Tan HL , Butler PC , Burke MD , Potter GA Salvestrols: a new perspective in nutritional research. J Orthomol Med. 2008;22: 40-47.

Karlgren M. , Gomez A. , Stark K. , et al. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun. 2006;341:451-458.

Peter GF , Chun YJ , Kim D. , Gillam EM , Shimada T. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies . Mutat Res. 2003;523-524:173-182.

Potter GA , Patterson LH , Wanogho E. , et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 2002;86:774-778. pp. 777

Yager JD , Davidson NE Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354:270-282.

Belous AR , Hachey DL , Dawling S. , Roodi N. , Parl FF Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Res. 2007;67:812-817.

Bruno RD , Njar VC Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development . Bioorg Med Chem. 2007;15:5047-5060.

Cheung YL , Kerr AC , McFadyen MC , Melvin WT , Murray GI Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours . Cancer Lett. 1999;139:199-205.

10.

Murray GI , Taylor MC , McFadyen MC , et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997;57: 3026-3031.

11.

Carnell DM , Smith RE , Daley FM , et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue . Int J Radiat Oncol Biol Phys. 2004;58:500-509.

12.

Gibson P. , Gill JH , Khan PA , et al. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development . Mol Cancer Ther. 2003;2:527-534.

13.

Downie D. , McFadyen MC , Rooney PH , et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005 ;11:7369-7375.

14.

Barnett JA , Urbauer DL , Murray GI , Fuller GN , Heimberger AB Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. 2007;13:3559-3567.

15.

Spivack SD , Hurteau GJ , Reilly AA , Aldous KM , Ding X. , Kaminsky LS CYP1B1 expression in human lung. Drug Metab Dispos . 2001;29:916-922.

16.

McFadyen MC , Melvin WT , Murray GI Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer. 2004;91: 966-971.

17.

McFadyen MC , Cruickshank ME , Miller ID , et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer. 2001;85:242-246.

18.

Maecker B. , Sherr DH , Vonderheide RH , et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 2003 ;102:3287-3294.

19.

Muskhelishvili L. , Thompson PA , Kusewitt DF , Wang C. , Kadlubar FF In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem. 2001 ;49:229-236.

20.

Kim JH , Sherman ME , Curriero FC , Guengerich FP , Strickland PT , Sutter TR Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol. 2004 ;199:210-219.

21.

Sissung TM , Price DK , Sparreboom A. , Figg WD Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention . Mol Cancer Res. 2006;4:135-150.

22.

Ding X. , Kaminsky LS Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003;43:149-173.

23.

McFadyen MC , Breeman S. , Payne S. , et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem. 1999;47:1457-1464.

24.

25.

McFadyen MC , Melvin WT , Murray GI Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther. 200;3:363-371.

26.

Tsuchiya Y. , Nakajima M. , Takagi S. , Taniya T. , Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006;66:9090-9098.

27.

Vainio H. , Weiderpass E. Fruit and vegetables in cancer prevention. Nutr Cancer . 2006;54:111-142.

28.

Juranic Z. , Zizak Z. Biological activities of berries: from antioxidant capacity to anti-cancer effects. Biofactors. 2005;23: 207-211.

29.

Seeram NP Berry fruits for cancer prevention: current status and future prospects . J Agric Food Chem. 200;56:630-635.

30.

Kundu JK , Surh YJ Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. In press.

31.

Chang TKH , Chen J. , Lee WBK. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001;299:874-882.

32.

Potter GA The role of CYP1B1 as a tumour suppressor enzyme. Br J Cancer . 2002;86:S12.

33.

Schaefer BA , Tan H. , Burke MD , Potter GA Nutrition and cancer: salvestrol case studies. J Orthomol Med. 2008;22:177.

34.

Magee JB , Smith BJ Resveratrol content of muscadine berries is affected by disease control spray program. HortScience. 2008;37:251.

35.

Daniel O. , Meier MS , Schlatter J. , Frischknecht P. Selected phenolic compounds in cultivated plants: ecologic functions, health implications, and modulation by pesticides. Environ Health Perspect. 1999;107(suppl 1):109-114.

36.

Sale S. , Verschoyle RD , Boocock D. , et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br J Cancer. 2004;90:736-744.

37.

Nebert DW , Dalton TP , Okey AB , Gonzalez FJ Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004;279: 23847-23850.

38.

Tokizane T. , Shiina H. , Igawa M. , et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 2005;11:5793-5801.

39.

Chokkalingam AP , Nyren O. , Johansson JE , et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer. 2003;98:1727-1734.

40.

Chang BL , Zheng SL , Isaacs SD , et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer. 2003 ;89:1524-1529.

41.

Chun YJ , Kim S. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents . Med Res Rev. 2003;23: 657-668.

42.

Kvistborg P. , Hadrup SR , Svane IM , Andersen MH , Straten PT Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients . Hum Immunol. 2008;69: 266-272.

43.

Sale S. , Tunstall RG , Ruparelia KC , et al. Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse. Invest New Drugs. 2006;24: 459-464.